Motor cortex repetitive transcranial magnetic stimulation in fibromyalgia: a multicentre randomised controlled trial
Primary resultResult — go to the resultOdds ratio 3.04 95% CrI 1.26–8.06Authors' conclusion
Add-on M1-repetitive transcranial magnetic stimulation reduced pain intensity up to 8 weeks in women with fibromyalgia. Although analgesic effects waned, functional improvements remained during extended maintenance at week 16.
Study context
- Population
- Women aged ≥18 yr with fibromyalgia refractory to best available treatment, Brazil, France and Japan
- Participants
- 101 women
- Comparison
- 10 Hz motor cortex repetitive transcranial magnetic stimulation (rTMS) vs sham stimulation
- Activen = 52
- Shamn = 49reference
- Primary endpoint
- ≥50% pain reduction vs baseline
- Follow-up
- Week 8
Methodological detailsdouble-blind, sham-controlled, multicentre, international, add-on therapy
- Double-blind
- Sham-controlled
- Multicentre
- International
- Add-on therapy
Primary result
As reported in the abstract
Odds ratio
3.04
95% CrI 1.26–8.06
Active vs Sham
OR 3.04 (95% CrI 1.26–8.06)
Secondary outcomes
Relative pain reduction (frequentist analysis) · week 8
P = 0.028
| Outcome | OR (95% CrI) | |
|---|---|---|
| ≥50% pain reduction · week 16Probability reduced to 34.2% · CrI (Bayesian analysis) | 0.815 (0.313–2.1) | |
| 0.20.5125Odds ratio (log scale) |
Fibromyalgia Impact Questionnaire (FIQ) score reduction · week 16
- Likelihood of FIQ score reduction
- 79.1%
Original publication
Motor cortex repetitive transcranial magnetic stimulation in fibromyalgia: a multicentre randomised controlled trial. Br J Anaesth. Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →